Citations

Clear

815 citation(s) found for "Tang, Yu".

407 Relationships between lymphocyte counts and clinical outcomes in patients with recurrent glioblastoma treated with pembrolizumab
Schultz, Sydney , Mohr, Riley T, Tang, Justin , Dong, Hongzhi , Campian, Jian , Amin, Md. Al , Mohr, Riley T, Karbhari, Nishika

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A463-A463

10.1136/jitc-2025-sitc2025.0407 Get It

Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B
Pan, Calvin Q. , Saadi, Samer , Feld, Jordan J., Lim, Joseph K. , Kim, A Y, Tang, Amy S. , Nguyen, Mindie H. , Sulkowski, Mark S. , Hegazi, Moustafa , Fleti, Farah, Abusalih, Mohamed F., Seisa, Mohamed O. , Allababidi, Adel Kabbara , Abbas, Alzhraa Salah , Mohammad, Khaled S., Abusalih, Mohamed , Hasan, Bashar , Kabbara Allababidi, Adel, Abbas, Alzhraa S, Saadi, Samer , Abusalih, Mohamed , Ghany, Marc G. , Nguyen, Mindie H. , Terrault, Norah A. , Lok, Anna S. , Hasan, Bashar , Nayfeh, Tarek , Abbas, Alzhraa Salah , Prokop, Larry J. , Murad, M. Hassan , Mohammad, Khaled S.

Mayo Clinic

Hepatology | November 4, 2025 | Volume: 83 | Issue: 4 | Pages: 998-1019

10.1097/hep.0000000000001584 | PMID 41186417 Get It

Background and Aims: With rapid changes in the management landscape of chronic hepatitis B (CHB), this technical systematic review addresses 4 critical Population, Intervention, Comparator, Outcome (PICO) questions to provide guidance to the formulation of recommendations to the 2025 AASLD practice guideline for management of CHB. Approach: The review was reported in accordance with PRISMA guidelines. Outcomes were evaluated across 4 key PICOs: (1) antiviral therapy for prevention of horizontal HBV transmission in high-risk groups, (2) antiviral therapy versus observation for persons in the immune-tolerant phase, (3) discontinuation versus continuation of nucleos(t)ide analogue therapy in HBeAg-negative individuals with undetectable HBV DNA, and (4) hepatocellular carcinoma (HCC) surveillance in non-cirrhotic individuals with HBsAg clearance or co-infections with HCV, HDV, or HIV. Results: For PICO 1, limited evidence suggests antiviral therapy may reduce horizontal transmission risk, though with low certainty. PICO 2 analyses reveal uncertain benefits of treating persons in the immune-tolerant phase, with very low certainty due to heterogeneity and bias. PICO 3 analyses demonstrate that discontinuing antiviral therapy in persons who are HBeAg negative with undetectable HBV DNA increases HBsAg loss rates (OR: 12.65, 95% CI: 1.58–101.51) but carries moderate risks of virologic relapse (OR: 47.17, 95% CI: 2.79–797.35) and clinical flares. PICO 4 analyses on several cohort studies showed that in patients co-infected with HCV, HBV, or HIV, the annual incidence of HCC was higher than the level where screening becomes cost-effective, suggesting that regular liver cancer screening could be beneficial for these patients. Conclusions: Despite low certainty, the findings support shared decision-making in high-risk horizontal transmission scenarios or in treating individuals in the immune tolerance phase, caution in discontinuing antiviral therapy in virologically suppressed individuals without HBsAg loss, and tailored HCC surveillance for those with co-infection or cirrhosis.
AASLD IDSA Practice Guideline on treatment of chronic hepatitis B
Ghany, Marc G. , Frick, Andrew , Lok, Anna S. , Feld, Jordan J. , Lim, Joseph K. , Wang, Su H. , Kim, A Y, Tang, Amy S. , Nguyen, Mindie H. , Naggie, Susanna, Sulkowski, Mark S. , Rodriguez‐Baez, Norberto, Chen, Jacki, Mohammad, Khaled S. , Kim, Arthur Y. , Naggie, Susanna , Pan, Calvin Q , Kim, Arthur Y , Naggie, Susanna , Murad, M Hassan , Mohammad, Khaled S , Terrault, Norah , Nguyen, Mindie H , Chen, Jacki, Terrault, Norah A.

Mayo Clinic

Hepatology | November 4, 2025 | Volume: 83 | Issue: 4 | Pages: 974-997

10.1097/hep.0000000000001549 | PMID 41186418 Get It

Background and Aims: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Methods: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline. Conclusions: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
Abstract 4370972: Impact of Aortic Annular Area on Outcomes Following Balloon-Expandable vs. Self-Expandable Valve-in-Valve Transcatheter Aortic Valve Replacement
Danesh, Sina , Sawma, Tedy, Banivaheb, Behrooz , Herrera, Harrison, Todd, Austin , Sawma, Tedy , Herrera, Harrison, Tang, Paul C.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4370972 Get It

Background: Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is an increasingly preferred strategy for managing failed surgical bioprosthetic valves, especially in high-risk patients. However, limited data exist comparing outcomes between balloon-expandable (BE) and self-expandable (SE) transcatheter heart valves (THVs) in this setting. The influence of aortic annular area on outcomes by valve type remains poorly understood. This study evaluated the impact of annular area on clinical outcomes following ViV-TAVR with BE vs. SE valves. Methods: We conducted a retrospective, single-center analysis of 353 patients who underwent ViV-TAVR between 2012 and 2024. All had prior surgical bioprosthetic AVR and received either BE (n=267) or SE (n=86) valves. Preprocedural multidetector CT was used to quantify aortic annular area. Transthoracic echocardiography was performed before and after the procedure to assess transvalvular gradients and hemodynamics. The primary endpoint was all-cause mortality. Penalized spline regression was used to model the nonlinear relationship between annular area and mortality and assess interaction by valve type. Results: Median age was 79 (IQR: 72–83) in the BE group and 80 (IQR: 76–85) in the SE group (p=0.07). Female sex was more common in the SE group (32% vs. 22%, p=0.047). Median annular area was 374 mm2 (IQR: 316–440) for BE and 365 mm2 (IQR: 308–432) for SE (p=0.081). Preprocedural gradient and effective orifice area index were 36 mm Hg (IQR: 28–46) and 0.6 cm2/m2 (IQR: 0.5–0.9), respectively, with no significant differences. Median hospital stay was 2 vs. 3 days (p=0.68). Thirty-day mortality was low (1 per group, p=0.36). Median follow-up was 4.0 years (IQR: 1.6–6.4). One- and 5-year survival rates were 94.75% and 61.7%, respectively (p=0.20). Penalized spline analysis showed a nonlinear association between annular area and mortality. The hazard ratio for BE valves declined with increasing annular area and fell below SE valves beyond ~400 mm2. Conclusion: ViV-TAVR is a safe and effective treatment for failed surgical bioprostheses. Smaller annular areas were associated with higher mortality. Outcomes with BE valves improved in larger annuli, suggesting annular area could guide valve selection. Further studies are warranted to validate these observations.
Proton Beam vs Intensity-Modulated Radiotherapy in Olfactory Neuroblastoma
Tang, Anthony , Krippaehne, Elise , Roozdar, Pooya, Goetschel, Kaitlin , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Snyderman, Carl H., Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Wang, Eric W., Olson, Brennan , Patel, Zara , Hwang, Peter H , Adida, Samuel , Donohue, Jack K. , Gago, Guilherme , Almeida, João Paulo , Nayak, Jayakar V. , Patel, Chirag, Pinheiro‐Neto, Carlos , Routman, David M. , Snyderman, Carl H , Gompel, Jamie J. Van , Wilke, Christopher , Wang, Eric W , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 30, 2025 | Volume: 152 | Issue: 1 | Pages: 60

10.1001/jamaoto.2025.3816 | PMID 41165699 Get It

Importance Adjuvant radiotherapy can improve locoregional control and survival in patients with olfactory neuroblastoma (ONB), particularly with advanced-stage and histologic-grade disease. Standard radiotherapy treatment is with intensity-modulated radiotherapy (IMRT). Proton beam radiotherapy (PBRT) provides theoretical advantages in greater sparing of dose to uninvolved organs at risk. Objective To investigate if there are differences in the effectiveness and radiation treatment–related adverse events (RTAEs) between adjuvant IMRT and PBRT for patients with ONB. Design, Setting, and Participants This propensity score–matched cohort study included patients with ONB treated between February 2005 and April 2021 with either IMRT or PBRT at 9 academic tertiary care centers in North America. Patients were matched 1:2 based on age, modified Kadish stage, and Hyams grade. Data were analyzed from July 2024 to January 2025. Exposure Adjuvant IMRT or adjuvant PBRT. Main Outcomes and Measures Local recurrence-free survival (RFS), any RFS, and overall survival (OS). RTAEs, ie, grade 2 events or higher based on Common Terminology Criteria for Adverse Events, were recorded for both modalities. Results Of 54 included patients, 27 (50%) were female, and the mean (SD) age was 46.2 (15.4) years. A total of 18 were treated with PBRT and 36 were treated with IMRT. Most patients had modified Kadish stage C disease (33 of 54 [61%]), and 24 patients (44%) had Hyams grade III or IV disease. The RTAE rate was 20% (8 of 40); IMRT had a rate of 21% (6 of 29), and PBRT had a rate of 18% (2 of 11). The difference in the point estimates for 10-year RFS showed a potential clinical benefit favoring IMRT, although the wide confidence interval indicates uncertainty (10-year RFS: IMRT, 63.3%; 95% CI, 44.6-89.8; PBRT, 37.8%; 95% CI, 14.2-100; difference, 25.5 percentage points; 95% CI, −17.6 to 68.6). There were no clinically meaningful differences in 10-year local RFS (IMRT, 75.6%; 95% CI, 59.8-95.4; PBRT, 72.7%; 95% CI, 45.2-100; difference, 2.9 percentage points; 95% CI, −35.9 to 41.7) or 10-year OS (IMRT, 61.8%; 95% CI, 42.8-89.1; PBRT, 57.1%; 95% CI, 24.3-100; difference, 4.7 percentage points; 95% CI, −49.2 to 58.6), although wide confidence intervals indicate considerable uncertainty. Conclusions and Relevance Due to the imprecision of estimates, no definitive conclusions can be made regarding the comparative effectiveness of IMRT vs PBRT for patients with ONB. These preliminary data may inform the design of appropriately powered prospective studies evaluating the efficacy of PBRT vs IMRT in this population.
Framework for Patient-Specific Hemodynamic Modeling of Left Ventricle Assist Device (LVAD) Patients
Bonini, Mia , Ferguson, Michael, Nordsletten, David , Hirschvogel, Marc , Pagani, Francis, Tang, Paul C

Mayo Clinic

No container title available | October 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7715752/v1 Get It

Abstract We present a high-fidelity, patient-specific computational framework for simulating cardiovascular hemodynamics in left ventricular assist device (LVAD) patients, with the ability to evaluate the impact of mitral and aortic valve repair. The method couples three-dimensional computational fluid dynamics (CFD) with a zero-dimensional lumped-parameter network representing the full cardiovascular system. Valve dynamics are governed by pressure–flow physics with patient-specific regurgitant areas, enabling the investigation of valve insufficiency and surgical repair. The model incorporates dynamic contrast-enhanced CT imaging, echocardiography, and catheter-based measurements. We demonstrate the utility of this framework using a clinical case involving a patient on long-term LVAD support with mitral regurgitation and aortic insufficiency. The coupled model resolves detailed pressure and velocity fields in the left heart, LVAD cannulae, and aortic root, while maintaining system-wide physiological consistency. Importantly, the framework also quantifies right ventricular loading and function, allowing assessment of how left-sided valve interventions propagate through the cardiopulmonary circulation. Using this pipeline, we simulate mitral and aortic valve repair by modulating valve closure mechanics and regurgitant area, revealing changes in both local and global hemodynamics. This modeling platform provides a powerful means to study the interplay between mechanical circulatory support, native valve physiology, and right heart function. It enables rigorous, patient-specific evaluation of surgical interventions in LVAD patients and delivers quantitative insight into clinically important metrics—such as aortic pulsatility, RV afterload, and chamber-level flow patterns—that are challenging to capture with current imaging modalities.
Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post‐Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest
Danesh, Sina , Khan, Fazal , Chopko, Trevor C. , Lee, Aurora , Huo, Ran , Shuyang, Lu, Tam, Vincy , Gao, Wenbin , Todd, Austin , Maleszewski, Joseph J. , Chen, Y. Eugene , Friedman, Paul A. , Oral, Hakan , Metra, Marco , Pitt, Bertram, Lei, Ienglam , Chopko, Trevor , Lu, Shuyang, Pagani, Francis D , Schaff, Hartzell , Chen, Y Eugene , Friedman, Paul A , Oral, Hakan , Pitt, Bertram , Tang, Paul C , Khan, Fazal Wahab , Metra, Marco , Huo, Ran, Tam, Vincy , Safi, J. Pedro , Todd, Austin, Pagani, Francis D. , Schaff, Hartzell V. , Pitt, Bertram , Tang, Paul C.

Mayo Clinic

Journal of the American Heart Association | October 9, 2025 | Volume: 14 | Issue: 20 | Pages: No page available

10.1161/jaha.125.043661 | PMID 41065249 Get It

Background Postoperative atrial fibrillation occurs in ~40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden. We evaluated the association of preoperative MRA use with postoperative atrial fibrillation and investigated atrial cell types modulated by MRAs during cold preservation. Methods We studied 19 042 cardiac surgery patients at Mayo Clinic. Propensity 1:3 matching identified 298 MRA users and 894 non‐users. A subgroup analysis of patients on any preoperative diuretic was performed to isolate cardiac‐specific effects of MRAs, matching 298 MRA users to 894 non‐MRA diuretic users. AF recurrence was assessed for up to 6‐years. Single‐nucleus RNA sequencing (snRNA‐seq) was performed on human donor atria exposed to canrenone (a water‐soluble MRA) during cold preservation with ex‐vivo reperfusion, and expression profiles were compared with atria from patients with AF. Results After matching, preoperative MRA use was associated with a lower incidence of postoperative atrial fibrillation (19.8% versus 31.8%, P <0.001). In the diuretic‐only subgroup, MRA users also had lower postoperative atrial fibrillation (19.8% versus 33.2%, P <0.001). MRA use was associated with a reduced incidence of paroxysmal and chronic AF at 6‐years. snRNA‐seq identified a cardiomyocyte subpopulation, CM2, with high mineralocorticoid receptor expression where canrenone suppressed cold preservation‐induced mineralocorticoid receptor target gene expression, which was conversely elevated in chronic AF. Canrenone also attenuated stress‐response in atrial macrophages and pericytes. Conclusions Preoperative MRAs were associated with reduced postoperative and long‐term AF after cardiac surgery. Mechanistically, our ex‐vivo human atrial model revealed that MRAs suppress mineralocorticoid receptor ‐driven atrial stress responses, particularly in conduction‐relevant cardiomyocytes.
Abstract Thu102: Brd4-mediated 3D chromatin architecture determines old donor heart preservation quality
Gao, Wenbin , Sicim, Hüseyin , Tang, Paul C. , Lei, Ienglam

Mayo Clinic

Circulation Research | October 8, 2025 | Volume: 137 | Issue: Suppl_1 | Pages: No page available

10.1161/res.137.suppl_1.thu102 Get It

Background: Heart transplantation is the gold standard treatment for end-stage heart failure patients. However, only about half of patients will receive a transplant, and hearts from donors >55 years of age are often not transplanted due to concerns about primary graft dysfunction (PGD). The molecular mechanisms behind the increased risk of PGD in old donor age are not well-known. Methods: We examine the chromatin architecture changes in old and young human donor hearts via HiC. We determine the effects of Brd4 inhibition on the on old mouse donor heart cold preservation quality via ex vivo perfusion. Results: we found that older human donor hearts are associated with upregulated BRD4 expression and increased chromatin accessibility. We also identified that human cardiac aging is associated with altered 3D chromatin architecture at BRD4 sites at baseline. Unexpectedly, the cold preservation process in older donor hearts further intensifies chromatin looping at BRD4 sites. Functionally, we showed that old murine donor hearts are more susceptible to cold preservation-reperfusion injury. Importantly, Brd4 inhibition with JQ1 improved the function of ex vivo cold-preserved old donor hearts, restoring them to levels comparable to young donor hearts. Moreover, AAV9-mediated Brd4 knockdown in cardiomyocytes similarly improved ex vivo old donor heart function after cold preservation. Conclusions: Brd4-associated 3D chromatin reorganization plays a critical role in the vulnerability of old donor hearts to cold preservation injury. Therefore, Brd4 could be a potential target for aging-associated PGD.
Enhancing Fairness and Accuracy in Diagnosing Type 2 Diabetes in Young Adult Population
Pias, Tanmoy Sarkar , Su, Y. P. , Tang, Xuxin , Wang, Haohui , Yao, Danfeng , Faghani, Shahriar

Mayo Clinic

IEEE Journal of Biomedical and Health Informatics | October 1, 2025 | Volume: 30 | Issue: 4 | Pages: 3321-3330

10.1109/jbhi.2025.3616312 | PMID 41032562 Get It